Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Deals End for Two R&D Companies
December 5, 2005
| A version of this story appeared in
Volume 83, Issue 49
Two contract chemistry research firms are planning reorganizations as multiyear agreements with Pfizer wrap up (C&EN, Oct. 31, page 14). Discovery Partners International expects a reduced need for combinatorial chemistry and library synthesis capacity because of the pending expiration. It will close its South San Francisco facility, except for its NIH-related compound management operations, in first-quarter 2006 and consolidate its business in San Diego. At Tripos, CEO John P. McAlister III anticipates that “a reorganization of Tripos Discovery Research may be necessary” as his firm's Pfizer deal draws to an end.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X